Kamada Reports Significant Financial Growth in Q3
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a biopharmaceutical company specializing in specialty plasma-derived products, recently announced compelling financial results for the third quarter and nine months ending September 30, 2025. The company recorded revenues of $47.0 million for Q3, marking a 13% year-over-year increase, alongside an adjusted EBITDA of $11.7 million, which reflects a robust 34% growth compared to the previous year.
Financial Highlights: Ninth Month Review
In the nine-month period, Kamada achieved total revenues of $135.8 million, a significant 11% increase from $121.9 million during the same timeframe in 2024. The adjusted EBITDA for this period reached $34.2 million, showcasing a substantial 35% increase year-over-year. The gross margin also showed improvement, rising to 44%, underlining the effective operational strategies implemented by the company.
Operational Achievements
The performance of Kamada can be attributed to its diverse product portfolio, which includes specialty plasma-derived therapies targeting rare diseases. This diversity not only aided in revenue generation but also facilitated an increase in gross profit, signaling efficient management of its product lines.
Future Outlook and Strategic Initiatives
As the company looks ahead, it maintains a positive outlook for the remainder of 2025, reaffirming its revenue guidance of between $178 million and $182 million, along with an adjusted EBITDA range of $40 million to $44 million. Management emphasizes that disciplined operational expense management will continue to support its growth initiatives.
Focus on R&D and Product Development
Kamada is committed to advancing its research and development initiatives, which includes the pivotal Phase 3 InnovAATe clinical trial for its inhaled Alpha-1 Antitrypsin therapy. The company is also progressing with its post-marketing study for CYTOGAM®, aiming to provide critical data related to cytomegalovirus management in organ transplants.
Cash Flow and Business Development
In terms of cash flow, Kamada generated $17.9 million from operational activities during the first nine months of 2025, reinforcing its strong cash position of $72.0 million as of September 30. This financial stability allows Kamada to further invest in business development opportunities, which include securing long-term plasma supply agreements and enhancing its operational capabilities.
Investments in Plasma Collection Operations
The company has recently expanded its plasma collection operations, including obtaining FDA approval for its Houston facility. This facility significantly boosts Kamada's operational capacity, set to contribute to increased revenue streams through sales of normal source plasma.
Conference Call Insights
Kamada's management will discuss these results and insights further in an upcoming conference call. This platform allows for investor engagement, fostering transparency about the company’s strategic direction and growth initiatives going forward.
Frequently Asked Questions
What were Kamada's revenues in Q3 2025?
Kamada reported revenues of $47.0 million in Q3 2025, representing a 13% increase compared to the same quarter last year.
How much did Kamada's adjusted EBITDA grow?
The adjusted EBITDA for Q3 2025 grew by 34% to reach $11.7 million, highlighting the company’s effective operational strategies.
What is Kamada expecting for full-year guidance?
Kamada has confirmed its full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million for 2025.
What strategic initiatives is Kamada pursuing?
Kamada is focusing on expanding its product portfolio, advancing R&D initiatives, and enhancing its plasma collection operations to support long-term growth.
How has Kamada improved its cash flow?
Kamada generated $17.9 million from operating activities and maintains a strong cash position of $72.0 million, reinforcing its financial stability for future investments.
